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Lack of Neointimal Proliferation After Implantation of
Sirolimus-Coated Stents in Human Coronary Arteries
A Quantitative Coronary Angiography and Three-Dimensional
Intravascular Ultrasound Study
J. Eduardo Sousa, MD, PhD; Marco A. Costa, MD, PhD; Alexandre Abizaid, MD, PhD;
Andrea S. Abizaid, MD; Fausto Feres, MD; Ibraim M.F. Pinto, MD; Ana C. Seixas, MD;
Rodolfo Staico, MD; Luiz A. Mattos, MD; Amanda G.M.R. Sousa, MD, PhD; Robert Falotico, PhD;
Judith Jaeger, BA; Jeffrey J. Popma, MD; Patrick W. Serruys, MD, PhD
Background—Restenosis remains an important limitation of interventional cardiology. Therefore, we aimed to determine
the safety and efficacy of sirolimus (a cell-cycle inhibitor)-coated BX Velocity stents.
Methods and Results—Thirty patients with angina pectoris were electively treated with 2 different formulations of
sirolimus-coated stents (slow release [SR], n515, and fast release [FR], n515). All stents were successfully delivered,
and patients were discharged without clinical complications. Independent core laboratories analyzed angiographic and
3D volumetric intravascular ultrasound data (immediately after procedure and at 4-month follow-up). Eight-month
clinical follow-up was obtained for all patients. There was minimal neointimal hyperplasia in both groups (11.063.0%
in the SR group and 10.463.0% in the FR group, P5NS) by ultrasound and quantitative coronary angiography (in-stent
late loss, 0.0960.3 mm [SR] and 20.0260.3 mm [FR]; in-lesion late loss, 0.1660.3 mm [SR] and 20.160.3 mm [FR]).
No in-stent or edge restenosis (diameter stenosis $50%) was observed. No major clinical events (stent thrombosis,
repeat revascularization, myocardial infarction, or death) had occurred by 8 months.
Conclusions—The implantation of sirolimus-coated BX Velocity stents is feasible and safe and elicits minimal neointimal
proliferation. Additional placebo-controlled trials are required to confirm these promising results. (Circulation. 2001;
103:192-195.)
Key Words: stents n restenosis n angioplasty
Restenosis remains a vexing problem of percutaneousintervention. The most promising approach to prevent
restenosis has been the application of intracoronary radia-
tion1; however, some relevant side effects (edge restenosis
and late thrombosis) have been reported.2,3 Numerous phar-
macological approaches to reduce restenosis have failed,
possibly due to insufficient local drug concentrations.4 De-
livering medication directly to the site of vascular injury via
polymeric-coated stents is a rational approach to achieve
adequate local drug delivery.5,6
Sirolimus (Rapamune), a natural macrocyclic lactone, is a
potent immunosuppressive agent that was developed by
Wyeth-Ayerst Laboratories and approved by the Food and
Drug Administration for the prophylaxis of renal transplant
rejection in 1999.7 Sirolimus binds to an intracellular receptor
protein and elevates p27 levels, which leads to the inhibition
of cyclin/cyclin-dependent kinase complexes and, ultimately,
induces cell-cycle arrest in the late G1 phase. It inhibits the
proliferation of both rat and human smooth muscle cells in
vitro8,9 and reduces intimal thickening in models of vascular
injury.10–12 However, the effects of the local administration of
sirolimus in a coated stent in humans have not been reported.
The aims of this pilot study were to assess (1) the
feasibility and safety of implanting 2 different formulations
of the sirolimus-coated BX Velocity stent in atherosclerotic
human coronary arteries and (2) the impact of the stents on
neointimal proliferation.
Methods
From December 1999 to February 2000, a single sirolimus-coated
BX Velocity stent was successfully implanted in each of 30
consecutive patients with coronary artery disease. The stent is a
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laser-cut, 316L stainless steel, balloon-expandable stent that contains
a fixed amount of sirolimus per unit of metal surface area (140 mg of
sirolimus per cm2).
Sirolimus was blended in a mixture of nonerodable polymers that
have been used clinically in bone cements, ocular devices, and a
drug-releasing intrauterine device.13,14 Fifteen patients received a
fast release (FR) formulation (,15-day drug release), and 15
received a slow release (SR) formulation ($28-day drug release).
Procedure
All stents were 18 mm long and 3.0 to 3.5 mm in diameter. After
predilatation of the target lesion, stents were deployed with high-
pressure (.14 atm) postdilatation guided by intravascular ultrasound
(IVUS). All patients received aspirin (325 mg/d, indefinitely), which
was started at least 12 hours before the procedure, and clopidogrel
(300 mg immediately after stent implantation and 75 mg/d for 60
days). The protocol was approved by the Medical Ethics Committee
of the Institute Dante Pazzanese of Cardiology, and informed
consent was obtained from every patient.
Quantitative Measurements
Quantitative coronary angiography (QCA) and IVUS imaging were
performed immediately after the procedure and at 4-month follow-up
in all patients after a bolus infusion of intracoronary nitrates. IVUS
images were acquired using motorized pull-back at a constant speed
of 0.5 mm/s. Quantitative angiographic and volumetric IVUS anal-
yses were performed by independent core laboratories (Brigham and
Women’s Hospital, Boston, Mass, and Cardialysis BV, Rotterdam,
The Netherlands, respectively).15–17 Three segments were selected
for volumetric IVUS analysis: the stented segment (18 mm long) and
2 edge segments that were axially 5 mm proximal and distal to the
stent margins.
Statistical Analysis
Continuous variables are expressed as mean6SD. Comparisons
between postintervention and follow-up measurements were per-
formed with a 2-tailed paired t test. Comparisons between groups
were performed using an unpaired Student’s t test. P,0.05 was
considered statistically significant.
Results
Twenty-six patients had stable angina and 4 patients had
unstable angina. Their mean age was 57.9610 years (SR) and
55.167 years (FR); 63% of the patients in each group were
male. The incidence of prior myocardial infarction was
33.3% (SR) and 53.3% (FR), and 14% (FR) and 26% (SR) of
the patients were diabetics. All stents were implanted suc-
cessfully, and all patients were discharged without complica-
tions 24 hours after treatment. Creatine kinase and creatine
kinase-MB levels, sampled at 6 and 18 hours after the
procedure, were within the normal range in all patients.
Angiographic and volumetric IVUS data are presented in
Tables 1 and 2. No patient approached $50% vessel narrow-
ing by QCA or IVUS, and only 3 patients had .15% intimal
hyperplasia (IH) by IVUS (Figure 1). In both the edge
segments and in the stented segment, lumen loss detected by
IVUS was minimal (Figure 2). All patients completed 4
months of angiographic and 8 months of clinical follow-up.
There were no repeat revascularizations, stent thromboses, or
major clinical events (cerebrovascular accident, myocardial
infarction, or death).
Discussion
This is the first human experience with the implantation of
sirolimus-coated BX Velocity stents. The absence of adverse
events for up to 8 months of follow-up suggests that the
implantation of this stent, which is coated with a potent
cell-cycle inhibitor, is feasible and safe.
The amount of IH after the implantation of noncoated
stents ranges from 19% to 48% of stent volume3,18,19 by
IVUS, and late loss averages 0.8 to 0.9 mm by QCA.19 Even
in nonrestenotic stents that are #15 mm long, an average IH
TABLE 1. Offline Quantitative Coronary Analysis by
Core Laboratory
Parameters SR Group (n515) FR Group (n515)
Before procedure
RD, mm 2.9860.4 2.9460.3
MLD, mm 1.1660.3 0.9360.4
DS, % 6267 68614
Lesion length, mm 12.961.97 13.162.2
Lesion type B1,* % 27 47
Lesion type B2,* % 73 33
After procedure
RD, mm 3.160.4 2.9660.3
In-lesion MLD, mm 2.7460.4 2.6860.3
In-stent MLD, mm 2.9460.44 2.8460.3
In-lesion DS, % 11.4465.5 9.765.8
In-stent DS, % 5.0966.72 4.267.4
Follow-up
RD, mm 2.9960.4 3.0760.3
In-lesion MLD, mm 2.660.5 2.760.4
In-stent MLD, mm 2.960.5 2.9360.3
In-lesion DS, % 14.569.1 12.768.2
In-stent DS, % 5.0466.7 4.5565.7
In-lesion late loss, mm 0.1660.3 20.0260.3
In-stent late loss, mm 0.0960.3 20.160.3
Values are mean6SD. RD indicates reference diameter; MLD, minimum
lumen diameter; and DS, diameter stenosis.
*According to AHA/ACC classification
Figure 1. Left, Cumulative distribution curves of percent IH in
SR and FR groups. Upper right panel shows follow-up IVUS
cross-section with largest amount of IH (17.5%), and lower right
panel displays IVUS cross-section with lowest amount of IH
(4.6%). In both vessels, a FR stent was implanted (arrows).
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of 19.7% has been observed by IVUS.18 Although differences
in population and stent design limit scientific comparison
with other reports, it is worth noting that the amount of IH
detected in the present study (10.7%; essentially zero late loss
by QCA) is much lower than previously reported. This is
likely due to the cytostatic effect of sirolimus.10–12,20
Using the same IVUS methodology, the amount of in-stent
IH with radioactive stent implantation varied from 7.4% (6 to
12 mCi radioactive stent) to 16.7% (0.75 to 1.5 mCi).17
However, neither edge restenosis nor stent thrombosis, both
of which have been reported after radiation,2,3 were observed
after the implantation of sirolimus-coated stents (Figure 2).
As a result of their permanent scaffolding action, stents
have become an attractive platform for delivering medica-
tions locally.5,21 Although some polymers have been associ-
ated with a marked inflammatory reaction,22 these findings
were not observed with the polymers used in the present
investigation or in other clinical situations.13,14 In the present
study, similar favorable results were observed with both the
FR and SR formulations of the sirolimus-coated stent.
Whether one sirolimus coating matrix is superior to the other
(SR versus FR) requires further investigation.
Limitations
The study comprises a registry of only 30 patients with 4
months of QCA and 3D IVUS data and 8 months of clinical
data. However, considering the absence of late loss by QCA
and the virtual absence of IH observed in the present study by
3D IVUS and the well-documented degree of late loss with
uncoated stents, these early results are promising. Twelve-
month angiographic and IVUS follow-up will be performed
in all patients to assess whether this effect is sustained.
Conclusion
Sirolimus-coated BX Velocity stents seem to be safe and
effective in preventing neointimal formation at 4 months after
stent implantation in de novo lesions. These seminal findings
warrant further confirmation by large, placebo-controlled,
multicenter trials.
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